EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Novel pathogenic variant in the LCAT gene in a compound heterozygous patient with fish-eye disease and a mild phenotype

Masaaki Miyata, Masayuki Kuroda, Junko Miyoshi, Mika Kirinashizawa, Rora Nagasawa, Misato Yamamoto, Yuichi Akasaki, Kensuke Utatsu, Yoshiro Maezawa, Koutaro Yokote, Mitsuru Ohishi

Journal of Clinical Lipidology · 2025

DOI: 10.1016/j.jacl.2024.09.013 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Clinical Lipidology, 2025. Verfasst von Masaaki Miyata und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan (Dr Miyata). Hauptthemen laut MEDLINE: Phosphatidylcholine-Sterol O-Acyltransferase, Heterozygote, Lecithin Cholesterol Acyltransferase Deficiency. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Government of Japan Ministry of Health Labour and Welfare, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Low high-density lipoprotein (HDL)-cholesterol and corneal opacity are associated with fish-eye disease (FED), familial lecithin:cholesterol acyltransferase (LCAT) deficiency (FLD), apolipoprotein AI deficiency, and Tangier disease. The differential diagnosis is made by clinical and biochemical tests. Measuring the LCAT activity is the ideal way to distinguish conditions caused by LCAT gene variants (FED and FLD) from the other 2 diseases. However, this is not accessible from all clinics. The cholesteryl ester/total cholesterol (CE/TC) ratio, which is below the reference range in most cases with LCAT gene variants, has been proposed as an alternative. We report a case of compound heterozygous FED with a CE/TC ratio within the reference range. METHODS: LCAT activity assays and genetic analyses were performed using patients' blood samples. Identified LCAT gene variants were examined by an in vitro expression assay. RESULTS: The proband showed approximately 20% LCAT α-activity relative to the normolipidemic controls, whereas a patient with a typical FED-causing variant (p.Thr147Ile) showed only 3% activity. We identified compound heterozygous variants (c.101C > T/c.460A > G) resulting in a p.Pro34Leu/p.Asn154Asp amino acid residue substitution in the LCAT gene of the proband. The former variant has been reported previously, but the latter was newly identified. An in vitro expression assay demonstrated that the LCAT α-activity of the p.Asn154Asp variant significantly decreased regarding the wild type, but it was relatively well preserved compared to the typical FED-causing variants (p.Pro34Leu and p.Thr147Ile). CONCLUSION: These results suggest that the residual 20% LCAT α-activity is sufficient to normalize CE/TC, but not sufficient to prevent the development of corneal opacity in FED.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphatidylcholine-Sterol O-AcyltransferaseHeterozygoteLecithin Cholesterol Acyltransferase DeficiencyHumansPhenotypeFemaleMaleAdult

Stichwörter der Autor:innen

Familial lecithin:cholesterol acyltransferase deficiencyFish-eye diseaseLow HDL-cholesterolemiacorneal opacitydifferential diagnosis

Substanzen

Phosphatidylcholine-Sterol O-AcyltransferaseLCAT protein, human

Autor:innen und Institutionen

  • School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan (Dr Miyata).
  • Center for Advanced Medicine, Chiba University Hospital, Chiba University, Chiba, Japan (Dr Kuroda). Electronic address: kurodam@faculty.chiba-u.jp.
  • CellGenTech, Chiba, Japan (Drs Miyoshi, Kirinashizawa, Nagasawa, and Yamamoto).
  • Department of Cardiovascular Medicine and Hypertension, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan (Dr Akasaki and Ohishi).
  • Department of Ophthalmology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan (Dr Utatsu).
  • Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba University, Chiba, Japan (Dr Maezawa and Yokote).

Förderung

  • Government of Japan Ministry of Health Labour and Welfare
  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Miyata, M., Kuroda, M., Miyoshi, J., Kirinashizawa, M., Nagasawa, R., Yamamoto, M., Akasaki, Y., Utatsu, K., Maezawa, Y., Yokote, K., & Ohishi, M. (2025). Novel pathogenic variant in the LCAT gene in a compound heterozygous patient with fish-eye disease and a mild phenotype. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2024.09.013

Vancouver

Miyata M, Kuroda M, Miyoshi J, Kirinashizawa M, Nagasawa R, Yamamoto M, et al. Novel pathogenic variant in the LCAT gene in a compound heterozygous patient with fish-eye disease and a mild phenotype. Journal of Clinical Lipidology. 2025. doi:10.1016/j.jacl.2024.09.013

BibTeX
@article{Miyata2025,
  author = {Miyata, Masaaki and Kuroda, Masayuki and Miyoshi, Junko and Kirinashizawa, Mika and Nagasawa, Rora and Yamamoto, Misato and Akasaki, Yuichi and Utatsu, Kensuke and Maezawa, Yoshiro and Yokote, Koutaro and Ohishi, Mitsuru},
  title = {Novel pathogenic variant in the LCAT gene in a compound heterozygous patient with fish-eye disease and a mild phenotype},
  journal = {Journal of Clinical Lipidology},
  year = {2025},
  doi = {10.1016/j.jacl.2024.09.013}
}
Kostenlos starten →